Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
Holding ITOS?
Track your performance easily
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.20 - $18.75
Previous Close$12.12
Volume960.79K
Average Volume (3M)482.82K
Market Cap
$442.46M
Enterprise Value-$123.28M
Total Cash (Recent Filing)$571.26M
Total Debt (Recent Filing)$5.52M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 06, 2024EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding36,521,845
10 Day Avg. Volume1,277,175
30 Day Avg. Volume482,818
Standard Deviation0.20
R-Squared0.12
Alpha-0.00205
Financial Highlights & Ratios
Price to Book (P/B)0.67
Price to Sales (P/S)12.63
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.52
Enterprise Value/Gross Profit-9.79
Enterprise Value/Ebitda1.19
Forecast
1Y Price Target
$34.25Price Target Upside195.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
iTeos Therapeutics News
PremiumCompany Announcements
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is moving the 400mg dose to Phase 3, which makes sense given the limited dose-response and high discontinuation rates in the 1000mg arm.
Efficacy DataThe data from the GALAXIES Lung-201 study presented at ESMO beat expectations, showing greater reduction of ctDNA with higher belrestotug doses linked to better survival.
ValuationThe current valuation is seen as an attractive entry point given the company has multiple shots on goal and enough cash to initiate multiple pivotal studies.
Bears Say
CompetitionEven though belrestotug and tiragolumab, if approved, could have first-to-market advantage in the anti-TIGIT space, they could eventually face strong competition from Fc-reduced/silenced anti-TIGIT therapies.
Drug SafetyThe safety data of the GALAXIES Lung-201 study confirms that Fc-competent anti-TIGIT antibodies are associated with increased risk of immune-related adverse events.
Treatment DiscontinuationDiscontinuation rates came in a bit high at the 1000mg dose.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $8.20 and its highest was $18.75 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$1.038 by $0.858.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$1.17.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 36,521,847 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$1.038. Following the earnings report the stock price went down -1.577%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 52M.
---
iTeos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (195.51% Upside)
$34.25 (195.51% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 864.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.66%
12-Months-Change
Fundamentals
Return on Equity
-16.80%
Trailing 12-Months
Asset Growth
6.83%
Trailing 12-Months
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Month Forecast
Average Price Target
$34.25
▲(195.51% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
-7.49%
assigned a buy rating 3 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -7.49% per trade.
---